Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
LQDA 
Liquidia Technologies Inc (LQDA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/17/2025: LQDA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $36.89
1 Year Target Price $36.89
| 6 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 85.87% | Avg. Invested days 40 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 10/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.94B USD | Price to earnings Ratio - | 1Y Target Price 36.89 |
Price to earnings Ratio - | 1Y Target Price 36.89 | ||
Volume (30-day avg) 10 | Beta 0.16 | 52 Weeks Range 9.71 - 29.94 | Updated Date 10/18/2025 |
52 Weeks Range 9.71 - 29.94 | Updated Date 10/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.82 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -424.41% |
Management Effectiveness
Return on Assets (TTM) -39.74% | Return on Equity (TTM) -389.13% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1912363842 | Price to Sales(TTM) 100.16 |
Enterprise Value 1912363842 | Price to Sales(TTM) 100.16 | ||
Enterprise Value to Revenue 98.97 | Enterprise Value to EBITDA -9.43 | Shares Outstanding 86091454 | Shares Floating 60759905 |
Shares Outstanding 86091454 | Shares Floating 60759905 | ||
Percent Insiders 13.36 | Percent Institutions 70.54 |
Upturn AI SWOT
Liquidia Technologies Inc
Company Overview
History and Background
Liquidia Technologies, Inc. was founded in 2004. It is a biopharmaceutical company focused on developing and commercializing products that address unmet medical needs by using its proprietary Particle Replication In Non-wetting Templates (PRINT) technology.
Core Business Areas
- Pulmonary Hypertension: Developing and commercializing inhaled therapies for pulmonary hypertension, particularly for pulmonary arterial hypertension (PAH).
- PRINT Technology: Using their proprietary PRINT technology to design and develop novel drug delivery systems.
Leadership and Structure
The company is led by a management team with experience in pharmaceutical development and commercialization. The organizational structure includes departments for research and development, clinical operations, regulatory affairs, and commercialization.
Top Products and Market Share
Key Offerings
- Yutrepia (Ralinepag): An inhaled dry powder formulation of ralinepag being developed for the treatment of pulmonary arterial hypertension (PAH). Yutrepia is the companies key offering. Competitors in the PAH market include United Therapeutics (UTHR) and Johnson & Johnson (JNJ).
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The pulmonary hypertension market is growing, driven by increasing prevalence and improved diagnosis.
Positioning
Liquidia is positioning itself as a player in the pulmonary hypertension market with its inhaled ralinepag product candidate. Its PRINT technology provides a potential competitive advantage in drug delivery.
Total Addressable Market (TAM)
The PAH market is estimated to be several billion dollars globally. Liquidia aims to capture a share of this TAM with Yutrepia, differentiating itself through its inhaled delivery method.
Upturn SWOT Analysis
Strengths
- Proprietary PRINT technology
- Targeted therapy for pulmonary hypertension
- Experienced management team
- Inhaled formulation for ease of use
Weaknesses
- Reliance on single product candidate (Yutrepia)
- Limited commercial infrastructure
- Competition from established players
- History of losses and need for additional funding
Opportunities
- Positive clinical trial results for Yutrepia
- Regulatory approval of Yutrepia
- Partnerships with larger pharmaceutical companies
- Expansion to other therapeutic areas using PRINT technology
Threats
- Clinical trial failures
- Regulatory delays or rejection
- Competition from existing and new therapies
- Patent challenges
- Generic entry
Competitors and Market Share
Key Competitors
- UTHR
- JNJ
Competitive Landscape
Liquidia's competitive advantage lies in its inhaled delivery method for ralinepag. However, it faces competition from established companies with broader product portfolios and greater resources.
Growth Trajectory and Initiatives
Historical Growth: Liquidia's historical growth has been primarily driven by the advancement of its product pipeline and the execution of collaboration agreements.
Future Projections: Future growth is dependent on the regulatory approval and commercial success of Yutrepia. Analyst estimates vary based on assumptions about market penetration and pricing.
Recent Initiatives: Recent initiatives include completing clinical trials for Yutrepia, preparing for regulatory submissions, and exploring potential partnerships.
Summary
Liquidia is a development-stage biopharmaceutical company with potential in pulmonary hypertension via Yutrepia. Success hinges on regulatory approval and commercialization, posing significant risk. Competition from established players and continued funding needs remain concerns. Their PRINT technology offers differentiation.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Liquidia Technologies Inc. SEC Filings
- Company Website
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and analyst estimates, which are subject to change. Investors should conduct their own research and consult with a financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Liquidia Technologies Inc
Exchange NASDAQ | Headquaters Morrisville, NC, United States | ||
IPO Launch date 2018-07-26 | CEO & Director Dr. Roger A. Jeffs Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 170 | Website https://www.liquidia.com |
Full time employees 170 | Website https://www.liquidia.com | ||
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.